EU approves first SGLT-2-class diabetes drug
The first product in the so-called SGLT-2-klass of drugs against type 2 diabetes has won backing from the European Union.
by Thomas Bo Christensen
The major players on the lucrative market for diabetes medicine face new competition from the first ever approved product in the newest class of drugs against type 2 diabetes – the so-called SGLT-2 drugs, as Astrazeneca and Bristol-Myers Squibb have had the pill Forxiga, which works independently of traditional insulin, approved for the European markets.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
